Herceptin and early breast cancer: a moment for caution

scientific article published on 01 November 2005

Herceptin and early breast cancer: a moment for caution is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0140-6736(05)67670-2
P698PubMed publication ID16291043

P433issue9498
P407language of work or nameEnglishQ1860
P304page(s)1673
P577publication date2005-11-01
P1433published inThe LancetQ939416
P1476titleHerceptin and early breast cancer: a moment for caution
P478volume366

Reverse relations

cites work (P2860)
Q532438562-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Q50611227Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage
Q55439955HER2 status in breast cancer--an example of pharmacogenetic testing.
Q35167009How much will Herceptin really cost?
Q37123317Media Hyping and the "Herceptin Access Story": An Analysis of Canadian and UK Newspaper Coverage
Q55206328Media influence on Herceptin subsidization in Australia: application of the rule of rescue?
Q37912288Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?
Q34546573Seven years of feast, seven years of famine: boom to bust in the NHS?
Q24200192Trastuzumab containing regimens for early breast cancer
Q24244420Trastuzumab containing regimens for early breast cancer
Q82265761Trastuzumab for early breast cancer
Q82730550Trastuzumab for early breast cancer
Q94468055Trastuzumab for early breast cancer
Q94468059Trastuzumab for early breast cancer
Q34564125Trastuzumab for early breast cancer: evolution or revolution?
Q80203516Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis
Q81295719Trastuzumab: possible publication bias

Search more.